OptimizeRx Corporation
OPRX
$7.77
$0.628.67%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 40.40% | 35.15% | 26.71% | 14.52% | -0.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.40% | 35.15% | 26.71% | 14.52% | -0.48% |
| Cost of Revenue | 30.40% | 29.58% | 30.37% | 21.88% | 4.50% |
| Gross Profit | 47.14% | 38.82% | 24.47% | 10.09% | -3.58% |
| SG&A Expenses | 13.71% | 13.17% | 8.74% | 10.24% | 12.88% |
| Depreciation & Amortization | 128.94% | 90.04% | 49.19% | 18.81% | -49.27% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.75% | 20.17% | 16.35% | 14.13% | 7.06% |
| Operating Income | 50.00% | 35.62% | 24.68% | -12.10% | -51.12% |
| Income Before Tax | -143.00% | -83.36% | -79.66% | -119.70% | -30.77% |
| Income Tax Expenses | -27,854.24% | -25,378.48% | -- | -- | -- |
| Earnings from Continuing Operations | -75.80% | -24.82% | -28.36% | -53.57% | -31.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.80% | -24.82% | -28.36% | -53.57% | -31.09% |
| EBIT | 50.00% | 35.62% | 24.68% | -12.10% | -51.12% |
| EBITDA | 71.24% | 51.49% | 35.48% | -10.80% | -57.77% |
| EPS Basic | -64.13% | -20.87% | -28.64% | -60.92% | -39.10% |
| Normalized Basic EPS | 10.21% | 7.82% | 9.05% | -16.46% | -38.75% |
| EPS Diluted | -65.46% | -21.91% | -29.67% | -62.16% | -37.12% |
| Normalized Diluted EPS | 10.21% | 7.82% | 9.05% | -16.46% | -37.96% |
| Average Basic Shares Outstanding | 6.85% | 2.34% | -1.10% | -3.70% | -5.47% |
| Average Diluted Shares Outstanding | 6.85% | 2.34% | -1.10% | -3.70% | -7.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
